NASDAQ:OPRX OptimizeRx - OPRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. $19.16 -0.22 (-1.14%) (As of 02/3/2023 12:01 PM ET) Add Compare Share Share Today's Range$18.84▼$19.3250-Day Range$15.90▼$21.0952-Week Range$13.33▼$49.24Volume36,718 shsAverage Volume152,279 shsMarket Capitalization$328.59 millionP/E RatioN/ADividend YieldN/APrice Target$41.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media OptimizeRx MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside117.6% Upside$41.00 Price TargetShort InterestBearish7.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.52) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.85 out of 5 starsComputer And Technology Sector413th out of 610 stocksBusiness Services, Not Elsewhere Classified Industry62nd out of 93 stocks 3.4 Analyst's Opinion Consensus RatingOptimizeRx has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.00, OptimizeRx has a forecasted upside of 117.6% from its current price of $18.84.Amount of Analyst CoverageOptimizeRx has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.26% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in OptimizeRx has recently increased by 3.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPRX. Previous Next 2.5 News and Social Media Coverage News SentimentOptimizeRx has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 3 news articles for OptimizeRx this week, compared to 3 articles on an average week.Search Interest9 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.50% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions80.45% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.52) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -32.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -32.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OptimizeRx (NASDAQ:OPRX) StockOptimizeRx Corp. is digital health company, engaging in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.Read More Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comFinancial Contrast: OptimizeRx (NASDAQ:OPRX) versus Helbiz (NASDAQ:HLBZ)January 21, 2023 | finance.yahoo.comWith 86% institutional ownership, OptimizeRx Corporation (NASDAQ:OPRX) is a favorite amongst the big gunsFebruary 3, 2023 | Investing Trends (Ad)The Humble Mineral at the Heart of the EV Revolution (Not Lithium)You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!January 4, 2023 | finance.yahoo.comOptimizeRx CEO Issues Open Letter to Shareholders Ahead of Presentation at J.P. Morgan Healthcare ConferenceNovember 28, 2022 | finance.yahoo.comOptimizeRx to Participate in Upcoming Investor ConferencesNovember 14, 2022 | finance.yahoo.comHere’s Why Artisan Partners Exited its Position in OptimizeRx Corporation (OPRX)November 10, 2022 | finance.yahoo.comOptimizeRx Third Quarter 2022 Earnings: EPS Beats ExpectationsNovember 8, 2022 | finance.yahoo.comOptimizeRx Corp. (OPRX) Tops Q3 Earnings EstimatesFebruary 3, 2023 | Investing Trends (Ad)The Humble Mineral at the Heart of the EV Revolution (Not Lithium)You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!November 8, 2022 | finance.yahoo.comOptimizeRx Reports Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comInvesting in OptimizeRx (NASDAQ:OPRX) five years ago would have delivered you a 228% gainOctober 25, 2022 | seekingalpha.comOptimizeRx: A Digital Health Marketing Firm That Has Fallen On Hard TimesOctober 19, 2022 | benzinga.comOptimizeRx Sets Third Quarter Fiscal 2022 Conference Call for Tuesday, November 8 at 4:30 p.m. ET - Optim - BenzingaOctober 19, 2022 | finance.yahoo.comOptimizeRx Sets Third Quarter Fiscal 2022 Conference Call for Tuesday, November 8 at 4:30 p.m. ETOctober 13, 2022 | seekingalpha.comOptimizeRx Stock: Top Candidate For My 'Bio Boom' Portfolio - Seeking AlphaOctober 12, 2022 | nasdaq.com5 Best Small-Cap Stocks for October 2022 - NasdaqOctober 11, 2022 | finance.yahoo.comCUVERD™, THE NEXT-GENERATION PRESCRIPTION SAVINGS PLATFORM, OFFERS PHARMACEUTICAL MANUFACTURERS A POWERFUL NEW INTEGRATED SOLUTION TO AMPLIFY ENROLLMENTS INTO PATIENT COPAY SAVINGS AND SUPPO - Yahoo FinanceOctober 11, 2022 | globenewswire.comOptimizeRx Announces Strong Results from its use of Previously Announced AI/RWE Solution - GlobeNewswireOctober 11, 2022 | finance.yahoo.comOptimizeRx Announces Strong Results from its use of Previously Announced AI/RWE SolutionSeptember 30, 2022 | reuters.comOPRX.ASeptember 23, 2022 | finance.yahoo.comIs OptimizeRx Corporation (NASDAQ:OPRX) Potentially Undervalued?September 20, 2022 | globenewswire.comOptimizeRx Extends Exclusive Partnership with ePrescribing Leader Therapy Brands - GlobeNewswireSeptember 20, 2022 | finance.yahoo.comOptimizeRx Extends Exclusive Partnership with ePrescribing Leader Therapy BrandsSeptember 8, 2022 | globenewswire.comFormer CEO of OptimizeRx to Put Millions of Dollars in Prescription Savings Right Into the Hands of Those Americans Looking for Relief - GlobeNewswireSeptember 7, 2022 | finance.yahoo.comOptimizeRx to Participate in Upcoming September ConferencesSeptember 4, 2022 | reuters.comOPRX.OQ - OptimizeRx Corporation | Stock Price & Latest News | ReutersAugust 28, 2022 | nasdaq.comFriday 8/26 Insider Buying Report: VPG, OPRXSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Company Calendar Last Earnings11/08/2022Today2/03/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Business services, not elsewhere classified Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees97Year FoundedN/APrice Target and Rating Average Stock Price Forecast$41.00 High Stock Price Forecast$76.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+114.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$380,000.00 Net Margins-16.62% Pretax Margin-16.63% Return on Equity-6.68% Return on Assets-6.33% Debt Debt-to-Equity RatioN/A Current Ratio16.19 Quick Ratio16.19 Sales & Book Value Annual Sales$61.29 million Price / Sales5.36 Cash Flow$0.13 per share Price / Cash Flow143.19 Book Value$7.39 per share Price / Book2.59Miscellaneous Outstanding Shares17,150,000Free Float16,553,000Market Cap$328.59 million OptionableNot Optionable Beta0.99 Key ExecutivesWill FebboChief Executive Officer & DirectorEdward StelmakhChief Operations & Financial OfficerTodd InmanChief Technology OfficerMarion K. Odence-FordChief Compliance Officer & General CounselAngelo CampanoSenior Vice President & Principal-Agency ChannelsKey CompetitorsEdgioNASDAQ:EGIOGravityNASDAQ:GRVYDHI GroupNYSE:DHXRimini StreetNASDAQ:RMNIUxinNASDAQ:UXINView All CompetitorsInsiders & InstitutionsKornitzer Capital Management Inc. KSBought 69,575 shares on 2/2/2023Ownership: 1.749%Simplex Trading LLCBought 2,200 shares on 2/2/2023Ownership: 0.000%Zurcher Kantonalbank Zurich Cantonalbank Bought 853 shares on 2/1/2023Ownership: 0.018%Rice Hall James & Associates LLCBought 73,728 shares on 1/27/2023Ownership: 1.585%Greenwood Capital Associates LLCBought 1,376 shares on 1/26/2023Ownership: 0.284%View All Insider TransactionsView All Institutional Transactions OPRX Stock - Frequently Asked Questions Should I buy or sell OptimizeRx stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks. What is OptimizeRx's stock price forecast for 2023? 5 brokers have issued 12-month price objectives for OptimizeRx's shares. Their OPRX share price forecasts range from $16.00 to $76.00. On average, they expect the company's stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 114.7% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts. How have OPRX shares performed in 2023? OptimizeRx's stock was trading at $16.80 at the beginning of the year. Since then, OPRX stock has increased by 13.7% and is now trading at $19.10. View the best growth stocks for 2023 here. When is OptimizeRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our OPRX earnings forecast. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) announced its earnings results on Tuesday, November, 8th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company earned $15.09 million during the quarter, compared to analyst estimates of $15.16 million. OptimizeRx had a negative net margin of 16.62% and a negative trailing twelve-month return on equity of 6.68%. What guidance has OptimizeRx issued on next quarter's earnings? OptimizeRx issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $62.00 million-$68.00 million, compared to the consensus revenue estimate of $64.05 million. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN). What is OptimizeRx's stock symbol? OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX." Who are OptimizeRx's major shareholders? OptimizeRx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kornitzer Capital Management Inc. KS (1.75%), Rice Hall James & Associates LLC (1.58%), Greenwood Capital Associates LLC (0.28%), Wesbanco Bank Inc. (0.10%), Yousif Capital Management LLC (0.07%) and Comerica Bank (0.06%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, Gregory D Wasson, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OptimizeRx's stock price today? One share of OPRX stock can currently be purchased for approximately $19.10. How much money does OptimizeRx make? OptimizeRx (NASDAQ:OPRX) has a market capitalization of $327.57 million and generates $61.29 million in revenue each year. The company earns $380,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. How can I contact OptimizeRx? OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529. This page (NASDAQ:OPRX) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.